Global Anti-obesity Drugs Market 2018-2022

抗肥満薬の世界市場2018-2022

◆タイトル:Global Anti-obesity Drugs Market 2018-2022
◆商品コード:IRTNTR23427
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2018年11月12日
◆ページ数:99
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆産業分野:医療・バイオ
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥378,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD5,000 ⇒換算¥540,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、抗肥満薬の世界市場について調査・分析し、市場概要、市場環境、抗肥満薬市場規模、肥満度別(クラスI、クラスII、クラスIII)分析、作用機序別分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・抗肥満薬の世界市場概要
・抗肥満薬の世界市場環境
・抗肥満薬の世界市場動向
・抗肥満薬の世界市場規模
・抗肥満薬の世界市場:業界構造分析
・抗肥満薬の世界市場:肥満度別(クラスI、クラスII、クラスIII)
・抗肥満薬の世界市場:作用機序別
・抗肥満薬の世界市場:地域別市場規模・分析
・抗肥満薬の北米市場規模・予測
・抗肥満薬のヨーロッパ・中東・アフリカ市場規模・予測
・抗肥満薬のアジア太平洋市場規模・予測
・抗肥満薬の主要国分析
・抗肥満薬の世界市場:意思決定フレームワーク
・抗肥満薬の世界市場:成長要因、課題
・抗肥満薬の世界市場:競争環境
・抗肥満薬の世界市場:関連企業情報(ベンダー分析)

98 pages, November 2018
About this market
The research on drugs that target obesity and type 2 diabetes mellitus to gain traction in the market. The global epidemic obesity and type 2 diabetes is increasing. This demands for increasing focus on the drugs that can control obesity and diabetes. Technavio’s analysts have predicted that the anti-obesity drugs market will register a CAGR of almost 8% by 2023.
Market Overview
Global increase in both incidence and prevalence of obesity
The prevalence and incidence rate of obesity is very high because of the limited efficacy of currently available drugs. The prevalence of obesity remains the highest in the US over the past two decades. Thus, the shoot in the rates of obesity across the world offers huge opportunities for drug manufacturing vendors to manufacture innovative and highly effective drugs.
Limited reimbursement for anti-obesity drugs
Although US is the major market for anti-obesity drugs, the challenges associated with the reimbursement of these drugs is more in the US. The bariatric surgery can recover weight related issues and is life-saving, but the concern for financial burden remains. People are unwilling to pay for this surgery as they believe that obesity is a cosmetic or lifestyle issue, which led player limit coverage.
For the detailed list of factors that will drive and challenge the growth of the anti-obesity drugs market during the 2018-2022, view our report.
Competitive Landscape
The market appears to be concentrated and with the presence of few companies including Eisai and Novo Nordisk the competitive environment is quite intense. Factors such as the increase in childhood obesity incidence and the use of implantable neuroregulatory devices for treating obesity, will provide considerable growth opportunities to anti-obesity drugs manufactures. Eisai, Novo Nordisk, and Vivus are some of the major companies covered in this report.

‘With the presence of a considerable number of companies, this market appears to be fragmented. This market to witness the presence of a few international and regional anti-obesity drug companies who offer obesity treatment drugs for mechanism such as centrally-acting and peripherally-acting anti-obesity drugs.’

【資料の目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 05: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast 2017-2022
PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 07: PIPELINE ANALYSIS
• Pipeline analysis
PART 08: MARKET SEGMENTATION BY DRUGS BASED ON CLASS OF OBESITY
• Segmentation by drugs based on class of obesity
• Comparison by drugs based on class of obesity
• Class I anti-obesity drugs – Market size and forecast 2017-2022
• Class II anti-obesity drugs – Market size and forecast 2017-2022
• Class III anti-obesity drugs – Market size and forecast 2017-2022
• Market opportunity by drugs based on class of obesity
PART 09: MARKET SEGMENTATION BY MECHANISM OF ACTION
• Segmentation by mechanism of action
PART 10: CUSTOMER LANDSCAPE
PART 11: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Americas – Market size and forecast 2017-2022
• EMEA – Market size and forecast 2017-2022
• APAC – Market size and forecast 2017-2022
• Market opportunity
PART 12: DECISION FRAMEWORK
PART 13: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 14: MARKET TRENDS
• Research on drugs that target both obesity and type 2 diabetes mellitus
• Increase in childhood obesity incidence
• Use of implantable neuroregulatory devices for treating obesity
• Increase in morbid obesity incidence
PART 15: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 16: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Eisai
• Novo Nordisk
• Vivus
PART 17: APPENDIX
• List of abbreviations



Exhibit 01: Parent market
Exhibit 02: Global metabolic disorder therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition – Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global – Market size and forecast 2017-2022 ($ mn)
Exhibit 09: Global – Year-over-year growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2017
Exhibit 18: Drugs based on class of obesity – Market share 2017-2022 (%)
Exhibit 19: Comparison by drugs based on class of obesity
Exhibit 20: Class I anti-obesity drugs – Market size and forecast 2017-2022 ($ mn)
Exhibit 21: Class I anti-obesity drugs – Year-over-year growth 2018-2022 (%)
Exhibit 22: Class II anti-obesity drugs – Market size and forecast 2017-2022 ($ mn)
Exhibit 23: Class II anti-obesity drugs – Year-over-year growth 2018-2022 (%)
Exhibit 24: Class III anti-obesity drugs – Market size and forecast 2017-2022 ($ mn)
Exhibit 25: Class III anti-obesity drugs – Year-over-year growth 2018-2022 (%)
Exhibit 26: Market opportunity by drugs based on class of obesity
Exhibit 27: Customer landscape
Exhibit 28: Global – Market share by geography 2017-2022 (%)
Exhibit 29: Regional comparison
Exhibit 30: Americas – Market size and forecast 2017-2022 ($ mn)
Exhibit 31: Americas – Year-over-year growth 2018-2022 (%)
Exhibit 32: Top three countries in Americas
Exhibit 33: EMEA – Market size and forecast 2017-2022 ($ mn)
Exhibit 34: EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 35: Top three countries in EMEA
Exhibit 36: APAC – Market size and forecast 2017-2022 ($ mn)
Exhibit 37: APAC – Year-over-year growth 2018-2022 (%)
Exhibit 38: Top three countries in APAC
Exhibit 39: Market opportunity
Exhibit 40: List of target drugs for obesity and type 2 diabetes mellitus
Exhibit 41: Vendor landscape
Exhibit 42: Landscape disruption
Exhibit 43: Vendors covered
Exhibit 44: Vendor classification
Exhibit 45: Market positioning of vendors
Exhibit 46: Eisai – Overview
Exhibit 47: Eisai – Business segments
Exhibit 48: Eisai – Organizational developments
Exhibit 49: – Geographic focus
Exhibit 50: Eisai – Key offerings
Exhibit 51: Novo Nordisk – Overview
Exhibit 52: Novo Nordisk – Business segments
Exhibit 53: Novo Nordisk – Organizational developments
Exhibit 54: Novo Nordisk – Geographic focus
Exhibit 55: Novo Nordisk – Segment focus
Exhibit 56: Novo Nordisk – Key offerings
Exhibit 57: Vivus – Overview
Exhibit 58: Vivus – Business segments
Exhibit 59: Vivus – Organizational developments
Exhibit 60: Vivus – Geographic focus
Exhibit 61: Vivus – Key offerings



【掲載企業】

Eisai、Novo Nordisk、Vivus

【免責事項】
※当資料上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当資料に記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当資料上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[抗肥満薬の世界市場2018-2022]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆